Kura Oncology
Dipanjan Sengupta is a highly experienced professional in the field of pharmaceutical development, currently serving as Director of API Process R&D at Kura Oncology, Inc. since August 2020. With a robust background in chemical development, Dipanjan has held notable positions at Mirati Therapeutics and STA Pharmaceuticals, where responsibilities included managing external manufacturing organizations and overseeing chemical development projects for drug substances in Phase II/III clinical trials. Previous roles at Ardea Biosciences and Dart Neuroscience involved leading process development and scale-up efforts for lead drug candidates. Dipanjan's career began in research at Miravant Pharmaceuticals, focusing on photodynamic therapy processes. Educational qualifications include a Ph.D. in Organic Chemistry from the Indian Association for the Cultivation of Science, complemented by postdoctoral research at prestigious institutions.
This person is not in any teams
Kura Oncology
20 followers
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.